Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 9007-9007 ◽  
Author(s):  
Noboru Yamamoto ◽  
Takashi Seto ◽  
Makoto Nishio ◽  
Koichi Goto ◽  
Isamu Okamoto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment

A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer

2020 ◽  
Vol 20 (6) ◽  
pp. 575-582 ◽  
Author(s):  
Susana Torres ◽  
Álvaro González ◽  
Alberto Jacobo Cunquero Tomas ◽  
Silvia Calabuig Fariñas ◽  
Macarena Ferrero ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Companion Diagnostic ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document